Validation of the OncoMasTR Risk Score in Estrogen Receptor-Positive/HER2-Negative Patients: A TransATAC study. Buus R, Sestak I, Barron S, Loughman T, et al. Clin Cancer Res 2020;26:623-631.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Buus R, Sestak I, Barron S, Loughman T, et al. Validation of the OncoMasTR Risk Score in Estrogen Receptor-Positive/HER2-Negative Patients: A TransATAC study. Clin Cancer Res 2020;26:623-631.
PMID: 31641007